SBIR/STTR Research Award
THE CONTRACTOR SHALL UTILIZE NANOPARTICLES TO DELIVER THE MPER-BASED IMMUNOGENS TO ELICIT BNABS AGAINST THE MPER OF HIV-1 GP41 TO DEVELOP A PROTECTIVE
Award amount
$300,000Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NEOVAXSYN INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- EHMTBALCKFE8
- Solicitation number
- PHS2020-1
- Topic code
- 77
Research abstract
Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to develop, evaluate, and optimize nanoparticle-based platforms to elicit broadly neutralizing antibodies against the membrane proximal external region (MPER) of the HIV-1 gp41 protein.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- NANOVACCINE FOR ELICITING BNABS AGAINST HIV-1
- DEVELOPMENT OF A NEXT-GENERATION IMMUNOPREVENTION PLATFORM AGAINST HIV-1
- Induction of bnAbs against HIV-1 gp41.
- Preclinical evaluation of HIV-1 envelope immunogens in humanized mice
- THE OBJECTIVE OF THIS CONTRACT IS TO UTILIZE GOLD NANOPARTICLES (GNP) TO ELICIT BROADLY NEUTRALIZING ANTIBODIES (BNABS) AGAINST THE FUSION PEPTIDE (FP
Research funding history
6 SBIR/STTR records share this UEI (2020–2024). Reported award amounts total $3,797,311. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services